4.7 Article

Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology

Journal

BLOOD
Volume 119, Issue 2, Pages 411-421

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-02-339911

Keywords

-

Categories

Funding

  1. European Community [518167]
  2. Ministero dell'Istruzione dell'Universita e della Ricerca [2002061255, 2007-ENYMAN_003, RBFR08CW8G]
  3. Alleanza Contro il Cancro and Istituto Superiore di Sanita
  4. Italian Association for Cancer Research (AIRC)
  5. Regione Lombardia (LIIN project)
  6. Fondazione Cariplo (NOBEL project)
  7. Fundacion Alfonso Martin Escudero
  8. Fondazione Cariplo
  9. Cancer Research UK [12077] Funding Source: researchfish

Ask authors/readers for more resources

In response to microenvironmental signals, macrophages undergo different activation, including the classic proinflammatory phenotype (also called M1), the alternative activation induced by the IL-4/IL-13 trigger, and the related but distinct heterogeneous M2 polarization associated with the anti-inflammatory profile. The latter is induced by several stimuli, including IL-10 and TGF-beta. Macrophage-polarized activation has profound effects on immune and inflammatory responses and in tumor biology, but information on the underlying molecular pathways is scarce. In the present study, we report that alternative polarization of macrophages requires the transcription factor c-MYC. In macrophages, IL-4 and different stimuli sustaining M2-like polarization induce c-MYC expression and its translocation to the nucleus. c-MYC controls the induction of a subset (45%) of genes associated with alternative activation. ChIP assays indicate that c-MYC directly regulates some genes associated with alternative activation, including SCARB1, ALOX15, and MRC1, whereas others, including CD209, are indirectly regulated by c-MYC. c-MYC up-regulates the IL-4 signaling mediators signal transducer and activator of transcription-6 and peroxisome proliferator-activated receptor gamma, is also expressed in tumor-associated macrophages, and its inhibition blocks the expression of protumoral genes including VEGF, MMP9, HIF-1 alpha, and TGF-beta. We conclude that c-MYC is a key player in alternative macrophage activation, and is therefore a potential therapeutic target in pathologies related to these cells, including tumors. (Blood. 2012;119(2):411-421)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available